- Teva Pharmaceutical Industries Ltd. is the world's largest generic drug manufacturer and is structurally Israeli in its deepest sense, with incorporation, governance, and profit consolidation all anchored in Israel. - Its BDS-1000 score of 520 (Tier C) is driven almost entirely by the V-ECON domain, reflecting ~$16.5 billion in annual global revenues that repatriate to the Israeli parent by operation of corporate law. - Teva's military-adjacent activity is limited and non-contractual, consisting primarily of a ~NIS 16 million medicine donation to Israeli hospitals and IDF field medical units following the October 2023 Hamas attacks. - The company is an end-user of commercial cloud and AI/ML tools — not a technology provider to any Israeli state body — placing its V-DIG domain contribution at minimal levels. - A single asymmetric solidarity statement issued on 11 October 2023, with no Palestinian-equivalent response, places Teva modestly above neutrality on V-POL but well short of active political advocacy.
Table of Contents
Teva Pharmaceutical Industries Ltd. is the world’s largest generic pharmaceutical manufacturer and one of Israel’s oldest continuously operating industrial enterprises — incorporated under Israeli law since 1901, headquartered in Tel Aviv, and constitutive of the TA-35 equity index. Its BDS-1000 score of 520 (Tier C) is driven almost entirely by the V-ECON domain, which scores at 8.0 out of a possible 10. This is not primarily a case of a foreign company maintaining business relationships with Israel; it is a case of a company that is Israeli in its deepest structural sense — domicile, governance, ownership, and profit consolidation are all anchored in Israel, and ~$16.5 billion in annual global revenues repatriate to the Israeli parent by operation of corporate law.12
The three remaining domains contribute modestly. V-MIL is low: Teva donated medicines — analgesics, antibiotics, and anaesthetics — valued at approximately NIS 16 million to Israeli hospitals and IDF field medical units following the October 2023 Hamas attacks, and its ~50% share of the Israeli generics market creates probable (though undocumented) routine supply channels to IDF healthcare. There are no defence contracts, weapons, construction activities, or tactical product variants.34 V-DIG is minimal: Teva is an end-user of AWS cloud infrastructure and an internal consumer of AI/ML tools, not a technology provider to any Israeli state body; the directionality is unambiguously that of a commercial software and cloud customer.5 V-POL is low-moderate: a single asymmetric solidarity statement issued on 11 October 2023 — with no Palestinian-equivalent statement and no active Israel-related lobbying identified — places Teva modestly above pure neutrality but well short of active political advocacy.67
The scoring formula’s OR-dominant structure means the secondary domains add only a fractional boost above V-ECON’s anchor of 8.0, yielding a composite BRS of 520. The Tier C classification is robust: it would require V-ECON to drop to approximately 6.0 to fall below 400, or to reach 9.5+ to break above 600 — neither scenario is supported by available evidence.
| Date | Event |
|---|---|
| 1901 | Teva founded in Jerusalem as Salomon, Levin, and Elstein Ltd.; incorporated under Israeli law throughout its history 8 |
| 1935 | “Teva” trademark adopted (Hebrew for “nature”) 8 |
| 1970s–1980s | Mergers with Assia and Zori pharmaceutical companies; Teva emerges as Israel’s dominant pharmaceutical manufacturer 8 |
| 2011 | Acquisition of Cephalon (U.S. specialty pharma); Teva becomes world’s largest generic manufacturer 9 |
| September 2015 | Multi-year IBM Watson Health collaboration announced for chronic-disease care management and drug-development analytics 10 |
| 2016 | Acquisition of Allergan Generics/Actavis (largest generics acquisition in history) and Anda Inc.; FCPA consent decree with U.S. DOJ 11 |
| December 2019 | AWS selected as Teva’s preferred global cloud provider; multi-year migration commitment announced 5 |
| 2017–2020 | Major global restructuring; ~14,000 positions eliminated globally, ~1,700 in Israel; Jerusalem, Ashdod, and Migdal Ha’Emek/Kiryat Shmona plants closed or sold; Israeli government ministers publicly engaged Teva management 12 |
| April 2021 | Project Nimbus (Israeli government cloud contract) awarded to Google Cloud and AWS; Teva has no vendor role in this programme 13 |
| 2022 | IBM divests Watson Health to Francisco Partners (rebranded Merative); Teva’s original IBM engagement treated as discontinued 10 |
| 2022 | Israeli Supreme Court rules against Teva in transfer-pricing dispute, confirming material profit repatriation from foreign subsidiaries to Israeli parent 14 |
| July 2022 | Teva reaches $4.25 billion U.S. opioid litigation settlement 15 |
| 2022 | Teva relocates global headquarters to Kiryat Atidim technology park, Tel Aviv 16 |
| 2023 | Richard Francis appointed President & CEO, succeeding Kåre Schultz 17 |
| 11 October 2023 | Teva issues public solidarity statement with Israel following Hamas attacks; announces ~NIS 16 million in medicine donations to Israeli hospitals and IDF field medical units 36 |
| FY2024 | Teva reports approximately $16.5 billion in consolidated global revenues 1 |
Teva Pharmaceutical Industries Ltd. is the world’s largest generic pharmaceutical manufacturer by volume and the largest pharmaceutical company in Israel. Founded in Jerusalem in 1901 as a wholesale drug distributor, Teva grew through domestic consolidation in the 1970s and 1980s before becoming a global force through a series of acquisitions — most significantly Cephalon (2011) and Allergan Generics/Actavis (2016).8 It remains incorporated under Israeli law and maintains its global corporate headquarters in Tel Aviv, making it one of the oldest continuously operating Israeli industrial enterprises.89
Teva’s commercial model spans three reported geographic segments — North America, Europe, and International Markets — generating approximately $16.5 billion in consolidated FY2024 revenues, the majority from the United States and Europe.1 Israel-specific domestic revenue is not separately disclosed but is estimated at the low hundreds of millions USD annually. The consolidated global profits of all subsidiaries worldwide flow upward to the Israeli parent entity, a mechanism confirmed by the 2022 Israeli Supreme Court tax ruling.14
The company operates manufacturing, R&D, and administrative infrastructure in Israel, with remaining active sites at Kfar Saba (oral solid dosage manufacturing), Netanya (R&D and specialty), and the Negev/Ramat Hovav region (API manufacturing), following site closures during the 2017–2020 restructuring.18 It is a constituent of the TA-35 Index on the Tel Aviv Stock Exchange, making it a core component of Israeli equity markets and a significant holding within Israeli pension fund portfolios.19 Teva’s governance structure is that of a standard Israeli public company under the Israeli Companies Law, with no golden shares or state ownership identified.9
Teva’s product portfolio covers generic oral solids, injectables, inhalers, biosimilars, active pharmaceutical ingredients, and specialty branded medicines (including the multiple-sclerosis drug Copaxone, developed in collaboration with the Weizmann Institute).20 It does not manufacture weapons, defence electronics, surveillance technology, agricultural products, or construction materials.
Teva’s relationship to Israeli military and security forces is limited, indirect, and non-contractual in its documented form. The company does not hold defence contracts, does not appear on SIBAT’s registry of Israeli defence-export companies, and has no disclosed weapons, munitions, construction, or tactical technology supply relationship with any military body.214
The most clearly documented military-adjacent activity is the wartime humanitarian donation made following the Hamas attacks of 7 October 2023. Teva publicly announced the donation of medicines — including analgesics, antibiotics, and anaesthetics — valued at approximately NIS 16 million to Israeli hospitals, Magen David Adom, and IDF field medical units.36 This was framed by Teva as a humanitarian response rather than a procurement contract. Israeli business press reported that Teva coordinated emergency drug supply directly to hospitals treating casualties and to IDF reservist medical kits. No evidence of a subsequent standing supply arrangement arising from this donation has been publicly documented.
The second mechanism is structural rather than contractual. Teva holds an estimated ~50% share of the Israeli generics market, making it a routine supplier to the national health basket (Sal Briut). This market dominance creates a high statistical probability that Teva’s generic medicines reach IDF Medical Corps healthcare channels through standard pharmaceutical distribution — not as a matter of a separately disclosed military contract, but as an inevitable consequence of market position. The State Comptroller has reported on pharmaceutical supply to Israel Prison Service (IPS) medical facilities without naming individual suppliers; Teva’s market dominance makes it a near-certain supply channel.224 The audit is explicit, however, that this constitutes civil healthcare procurement rather than a defence contract.
An evidence gap of moderate significance concerns CBRN medical countermeasures. Israel maintains civil-defence CBRN stockpiles including atropine auto-injectors distributed to civilians and military personnel. Whether Teva manufactures these specific auto-injectors for the IDF or Home Front Command is not publicly documented. If confirmed, this would represent purposive military supply rather than incidental market-channel provision, and could modestly increase the I-MIL score toward 2.5. However, no positive evidence exists; this gap is flagged but does not affect the current scoring.
The nature of Teva’s supply — generic pharmaceuticals including atropine, morphine, epinephrine, ciprofloxacin, and amoxicillin — places it firmly in the category of standard civilian-specification medicines that militaries worldwide stock as routine medical supplies. These are not purpose-built military variants, not ruggedised, not packaged to mil-spec, and not subject to ITAR, Wassenaar Arrangement controls, or EU Dual-Use Regulation Annex I. Teva’s industrial capabilities are pharmaceutical API synthesis and finished-dose formulation — not electronics, optics, structural metals, propellants, or guidance systems.921
The rubric mapping for V-MIL is therefore as follows. Impact (I = 1.8) falls in the Incidental band: civilian pharmaceutical goods supplied to military healthcare via market dominance, with the wartime donation being non-lethal and non-tactical. Magnitude (M = 2.5) is Very Low–Low: the NIS 16 million donation was a single documented event; the ongoing market-channel supply involves easily substitutable generic medicines. Proximity (P = 3.2) is Low: Teva was the direct donor for the documented event but market-channel supply is more indirect and mediated by standard pharmaceutical distribution chains.
The principal counter-argument to the low V-MIL score is the CBRN evidence gap. If Teva is the IDF’s supplier of atropine auto-injectors and nerve-agent antidote kits — a role that would constitute purposive, non-substitutable military procurement — the I-MIL score could plausibly rise toward 2.5–3.0, and the characterisation of supply as “incidental” would weaken. However, this remains a zero-evidence gap: no positive evidence of such supply exists, and the appropriate analytical response is to flag the gap rather than infer from it.
A second counter-argument concerns the framing of the wartime donation. The donation was publicly announced and framed as humanitarian, but the practical effect was direct supply of medicines to IDF field medical units. Activists and some civil society researchers have argued that the distinction between “humanitarian donation” and “military medical supply” is partly semantic when the recipient is an active military force conducting combat operations. The audit acknowledges this tension but notes that Teva’s own framing, the non-tactical nature of the products, and the absence of a recurring contract all support the lower end of the Incidental band.
A third limitation is the absence of a granular site-level audit of Teva’s manufacturing and distribution facilities. While principal sites (Kfar Saba, Netanya, Ramat Hovav) are within Israel’s pre-1967 lines, a complete audit from open sources alone was not feasible for all storage and distribution nodes. This gap is assessed as low significance given the broader absence of any settlement-economy findings across multiple NGO databases.2223
No major NGO — Who Profits, AFSC, Corporate Watch, Norges Bank NBIM, or the BDS National Committee — has documented a specific military supply-chain finding for Teva or taken institutional action on this basis.22232425
| Entity | Type | Role / Relevance |
|---|---|---|
| Teva Pharmaceutical Industries Ltd. | Subject | Direct donor of NIS 16m medicines to IDF field units; dominant Israeli generics supplier |
| IDF Medical Corps | Israeli military body | Recipient of wartime medicine donation; probable routine generics customer via market channels |
| Magen David Adom | Israeli emergency service | Co-recipient of October 2023 medicine donation |
| Israel Prison Service (IPS) | Israeli security body | Probable Teva customer via market-dominant generics supply; no contract named |
| SIBAT | Israeli MoD export registry | Teva absent from registry |
| Who Profits Research Center | NGO | Profiles Teva; does not classify it as military/security company |
| AFSC Investigate | NGO | Profiles Teva; no military supply-chain finding |
| BDS National Committee | Civil society | Does not list Teva on primary boycott target list |
| Norges Bank NBIM | Institutional investor | Has not excluded Teva; has excluded Elbit Systems |
| Weizmann Institute / Yeda R&D | Academic/IP | Copaxone origin; pre-2020 royalty relationship; no military relevance |
| Home Front Command | Israeli military body | Potential CBRN antidote stockpile authority — unconfirmed supply relationship |
Teva’s digital footprint is that of a large pharmaceutical company consuming technology services from major international vendors — not of a technology producer, platform operator, or provider of digital services to state bodies. This distinction is material to the V-DIG scoring and is supported by convergent evidence across multiple source classes.
The primary cloud relationship is with Amazon Web Services. In December 2019, Teva publicly selected AWS as its preferred global cloud provider, committing to a multi-year engagement covering migration of SAP workloads and core enterprise applications.5 AWS is a U.S.-origin company with no Israeli state-ownership interest. Teva is a cloud consumer in this relationship, paying for infrastructure and services; it does not resell, operate, or otherwise pass on AWS capacity to third parties, including any Israeli government body. This is an enterprise IT procurement decision standard for a company of Teva’s scale.
Teva’s enterprise resource planning backbone is SAP, a German company, referenced across investor filings and ESG disclosures.26 The IBM Watson Health collaboration (announced September 2015) covered Watson-based analytics for chronic-disease care management and drug-development decision support.10 IBM divested Watson Health to Francisco Partners in 2022; Teva’s original engagement is treated as discontinued in its original form. Within its AI/ML function, Teva uses cloud-based tools — primarily via AWS — for drug-discovery pipelines, manufacturing-process analytics, pharmacovigilance signal detection, and patient-support platforms. These are internal operational uses; no AI or algorithmic system supplied by Teva to Israeli state agencies, military units, or security services has been identified.26
A systematic check across Teva’s Form 20-F filings, ESG Progress Report, corporate press releases, and NGO databases found no confirmed licensing, subscription, or integration relationship with any Israeli-founded or Israeli-headquartered technology vendor — including Check Point Software, CyberArk, Wiz, SentinelOne, Claroty, NICE Systems, Verint Systems, or Palo Alto Networks.926 Similarly, surveillance and biometric platforms of Israeli origin — Trigo, BriefCam, AnyVision/Oosto, Trax — returned no results across all reviewed sources. Teva is a pharmaceutical manufacturer and distributor; it does not operate customer-facing physical retail premises where such technology would be deployed.
Project Nimbus, the Israeli government’s national cloud contract awarded jointly to Google Cloud and AWS in April 2021, is directly relevant as a potential indirect exposure vector.13 Teva is not a Project Nimbus vendor. As an AWS customer with Israeli operations, Teva may consume capacity from the AWS Israel region that physically overlaps Nimbus infrastructure, but this cannot be confirmed or excluded from available sources and is assessed as speculative rather than evidentiary. The rubric’s Customer Cap and Directionality Rule firmly cap Teva’s V-DIG Impact at ≤3.9 regardless of this uncertainty.
The scoring follows directly from this profile. Impact (I = 2.0) reflects Teva’s status as a buyer of cloud and AI services with no technology provision to Israeli state bodies; the Customer Cap prevents this from reaching the higher bands applicable to technology providers or vendors. Magnitude (M = 1.5) is Very Low: no Israeli-origin software procurement is confirmed, and the AWS engagement is for internal enterprise operations only. Proximity (P = 1.5) is Very Low: Teva as cloud consumer has no structural relationship to Israeli state technology deployment; AWS is a U.S.-origin company with no Israeli government ownership.
The most plausible challenge to the V-DIG score involves undisclosed procurement of Israeli-origin enterprise software. It is common for large multinationals to deploy security, analytics, or network-management tools from Israeli-founded vendors — Check Point, CyberArk, and SentinelOne in particular have deep enterprise penetration — without specifically disclosing vendor names in public filings. If Teva pays licence fees to, for example, Check Point for endpoint security, this would represent Israeli-origin technology procurement. The audit’s finding is “no public evidence identified” rather than a positive confirmation of absence.
However, even if this gap were resolved negatively (i.e., Teva does use Israeli-origin enterprise security software), the Customer Cap would still apply. A worst-case scenario — Teva confirmed as a paying customer of multiple Israeli cybersecurity vendors — would move I-DIG to approximately 3.5 under the Customer Cap ceiling of 3.9. At M = 2.5 and P = 2.5, this would yield V-DIG ≈ 0.32, still negligible in the composite score. The directionality constraint (Teva as buyer, not seller or provider) is structural and does not depend on which specific vendors are involved.
A second limitation is the Kiryat Atidim co-location. Teva’s 2022 relocation of its global headquarters to the Kiryat Atidim technology park in Tel Aviv places it in physical proximity to Israel’s digital-health and deep-tech ecosystem.16 No documented technology-transfer, joint-development, or commercial partnership arising from this co-location has been identified in public sources, but informal knowledge-sharing or early-stage partnership activity below the threshold of SEC disclosure cannot be excluded from open-source review alone.
A third gap concerns Teva’s participation in Israeli digital-health innovation programmes referenced in Israel Innovation Authority annual reporting.27 Specific limited-partner positions in Israeli venture-capital funds or named minority investments in Israeli ICT startups are not enumerated in public filings. This gap is assessed as low significance for V-DIG scoring, since even confirmed VC positions would not constitute technology provision to Israeli state bodies.
| Entity | Type | Role / Relevance |
|---|---|---|
| Amazon Web Services (AWS) | U.S. cloud vendor | Teva’s preferred global cloud provider since Dec 2019; Teva is end-user/buyer |
| SAP | German ERP vendor | Teva’s global ERP backbone; ongoing relationship |
| IBM Watson Health / Merative | U.S. analytics vendor | 2015–2022 collaboration; discontinued in original form post-divestiture |
| Project Nimbus | Israeli government cloud programme | Awarded to AWS and Google; Teva is not a vendor; indirect exposure unconfirmed |
| Kiryat Atidim (Tel Aviv) | Technology park | Teva global HQ since 2022; co-location with tech sector noted, no tech-transfer documented |
| Israel Innovation Authority | Israeli state body | Cited in R&D incentive context; Teva participation in digital-health programmes referenced but not enumerated |
| BDS National Committee | Civil society | Explicitly states it does not target Teva |
| Check Point, CyberArk, Wiz, SentinelOne | Israeli-origin cybersecurity vendors | Checked; no confirmed Teva relationship |
| Trigo, BriefCam, AnyVision/Oosto, Trax | Israeli-origin surveillance vendors | Checked; no confirmed Teva relationship |
| NICE Systems, Verint Systems | Israeli-origin analytics vendors | Checked; no confirmed Teva relationship |
The V-ECON domain is the structural core of Teva’s BDS-1000 score. The key analytical point is that Teva is not a foreign company with economic ties to Israel; Teva is an Israeli company, in every meaningful sense of that phrase — legal domicile, corporate governance, global headquarters, profit consolidation, and institutional identity are all anchored in Israel. This foundational status maps to the “Acquired Identity / High (Mid)” impact band and produces the dominant domain score of V_ECON = 8.0.
Teva traces its founding to 1901, when it was established in Jerusalem as Salomon, Levin, and Elstein Ltd.8 It has been incorporated under the laws of the State of Israel throughout its entire 120+ year history — one of the oldest continuously operating Israeli industrial enterprises. The Hebrew name “Teva” (nature), formally adopted in 1935, signals a deliberate anchoring in Israeli cultural identity. Mergers in the 1970s and 1980s with Assia and Zori pharmaceutical companies produced Israel’s dominant pharmaceutical manufacturer; global expansion through Cephalon (2011) and Actavis Generics (2016) made it the world’s largest generics producer, but the Israeli parent entity remained the legal and operational anchor throughout.89
The profit repatriation mechanism is documented with unusual clarity by primary legal evidence. The 2022 Israeli Supreme Court ruling in Teva’s tax dispute explicitly confirmed that foreign-subsidiary profits repatriated to the Israeli parent are subject to Israeli taxation.14 This ruling establishes — as a matter of Israeli domestic law applied to Teva specifically — that real and material economic flows from ~60 country-level subsidiaries across North America, Europe, and international markets consolidate upward to the Israeli parent. Total consolidated revenues of approximately $16.5 billion (FY2024)1 therefore represent the scale of global economic activity flowing to the Israeli corporate entity. Even discounting the Israeli domestic market contribution (estimated at low hundreds of millions USD), the consolidated global parent in Tel Aviv is the economic beneficiary of the entire enterprise.
Teva’s role in the Israeli equity market is constitutive rather than peripheral. As a TA-35 Index constituent on the Tel Aviv Stock Exchange, Teva is a core component of the benchmark that Israeli pension funds, insurance companies, and institutional investors track.19 An Israeli citizen passively investing in an index-tracking retirement product almost certainly holds Teva exposure. This systemic role in Israeli capital markets is a distinct form of economic integration beyond mere tax contributions or employment — it means Teva’s performance directly affects the financial security of Israeli households.
Tax incentives under Israel’s “Approved Enterprise” and “Preferred Enterprise” programmes confirm the mutual economic relationship between Teva and the Israeli state.9 These programmes provide reduced corporate tax rates on qualifying Israeli-source income, representing a direct financial subsidy from the Israeli Treasury to Teva’s operations. This subsidy relationship — in addition to the profit-flow relationship — establishes a two-way economic integration: the Israeli state supports Teva through concessional taxation, and Teva’s global profits consolidate into the Israeli parent, generating taxable income and employment at home.
Teva’s R&D infrastructure in Israel is treated by the company itself as strategically central, not peripheral. The Netanya R&D centre was highlighted in Teva’s 2023 Investor Day “Pivot to Growth” strategy presentation as a core long-term asset.28 Additional R&D functions at Kfar Saba contribute to global pharmaceutical pipeline development. The Israeli R&D footprint is not simply a legacy of founding geography; it is an actively maintained competitive asset explicitly identified in forward-looking strategy.
The Magnitude score (M = 8.5) reflects systemic importance: largest Israeli pharmaceutical company, TA-35 anchor, hundreds of millions in domestic revenue, R&D central to long-term strategy, and a government response to the 2017 restructuring that confirms national-scale economic significance. When Israeli government ministers publicly engaged Teva management over the closure of the Jerusalem manufacturing facility and the elimination of ~1,700 Israeli positions, they were signalling that Teva’s operational decisions are treated as matters of national economic policy — not corporate events affecting a peripheral employer.12 The Proximity score (P = 9.8) is at the Extreme band because Teva itself is the Israeli entity; there is no intermediary between the subject of this dossier and the Israeli economic system.
The principal counter-argument to the high V-ECON score is the observation that the majority of Teva’s revenue — roughly 80–85% — is generated in North America and Europe, not in Israel. An analyst focused on operational footprint rather than legal domicile might argue that Teva is “really” an American or European company that happens to be incorporated in Israel for historical reasons. This argument is weak on the available evidence for two reasons. First, the profit-repatriation mechanism confirmed by the Supreme Court ruling means that North American and European revenues ultimately flow to the Israeli parent regardless of where they are operationally generated. Second, the Israeli government’s treatment of Teva’s restructuring decisions as events of national economic significance demonstrates that Israeli state institutions themselves regard Teva as a domestic entity, not a foreign investor.
A second counter-argument concerns the lack of Israeli government ownership or golden shares. Unlike some national champions, Teva has no state shareholder and no government-appointed directors.9 Its governance is standard institutional public-company structure. This is acknowledged in the scoring: the absence of direct state ownership is why Impact falls at 8.0 (High Mid / Acquired Identity) rather than 9.5–10.0 (Extreme / Strategic-National Infrastructure). The Acquired Identity band explicitly accommodates companies that are foundationally Israeli without being state-owned.
A specific evidence gap concerns the precise quantum of Israeli domestic revenue and Israeli-source R&D expenditure as shares of global totals. These are not separately disclosed in segment reporting. The scoring does not depend on these figures — Proximity is already at 9.8 because Teva is the Israeli parent entity, not a subsidiary or distributor — but precise figures would allow more granular calibration of Magnitude. This gap does not affect the tier classification.
The closure of Israeli manufacturing sites during the 2017–2020 restructuring (Jerusalem, Ashdod, Migdal Ha’Emek/Kiryat Shmona) is a material reduction in the domestic operational footprint.12 However, the remaining sites at Kfar Saba, Netanya, and Ramat Hovav remain significant, the Israeli R&D function is explicitly described as strategically central, and the legal domicile, HQ, and profit consolidation are unchanged. The restructuring affected the magnitude of domestic employment but not the foundational character of the Israeli identity.
| Entity | Type | Role / Relevance |
|---|---|---|
| Teva Pharmaceutical Industries Ltd. | Subject | Israeli-domiciled ultimate parent; TA-35 constituent; founded 1901 |
| Tel Aviv Stock Exchange (TASE) | Israeli financial institution | TA-35 Index; Teva is constituent anchor stock |
| TA-35 Index | Israeli equity benchmark | Teva constituent; systemic role in Israeli pension portfolios |
| Israel Tax Authority | Israeli state body | Transfer-pricing dispute; 2022 Supreme Court ruling confirmed profit repatriation |
| Israeli Supreme Court | Israeli judiciary | 2022 ruling confirmed foreign-subsidiary profits subject to Israeli parent taxation |
| Israel Innovation Authority | Israeli state body | R&D incentive programmes; Teva beneficiary |
| “Preferred Enterprise” / “Approved Enterprise” programmes | Israeli fiscal instruments | Reduced corporate tax rates on qualifying Israeli-source income |
| Kfar Saba facility | Manufacturing site | Active; oral solid dosage manufacturing |
| Netanya facility | R&D and manufacturing site | Active; global innovation centre; central to “Pivot to Growth” strategy |
| Ramat Hovav / Negev facility | API manufacturing site | Active; chemical synthesis |
| Jerusalem facility | Manufacturing site (closed) | Closed 2018; closure prompted government intervention |
| Ashdod / Migdal Ha’Emek facilities | Manufacturing sites (closed/sold) | Closed during 2017–2020 restructuring |
| Weizmann Institute / Yeda R&D Co. | Academic/IP origin | Copaxone licensing origin; pre-2020 royalty relationship |
| NYSE (TEVA) | U.S. exchange | ADR listing; widely held institutional shareholder base |
| Richard Francis | CEO | Current leadership; earnings call commentary on conflict |
| Kåre Schultz | Former CEO | Led 2017–2022 restructuring |
Teva’s political posture is characterised by asymmetric corporate communication and standard pharmaceutical lobbying activity, with no evidence of active advocacy on Israel-related political matters. The company falls in the Low-Mid (Business-as-Usual with marginal deviation) band of the V-POL rubric.
The most significant documented political act is the corporate statement issued on 11 October 2023, days after the Hamas attacks, expressing solidarity with Israel and announcing humanitarian aid contributions.63 The statement was attributed to company leadership and reported in financial and pharmaceutical trade press. CEO Richard Francis subsequently commented on the conflict’s operational implications during earnings calls, framing Teva’s Israeli headquarters and manufacturing presence as operationally resilient while acknowledging the human toll on employees and their families.3 This is a documented, direct corporate act with Teva’s own name and attributed to identified leadership.
The asymmetry is the analytically relevant feature. Teva has not issued a comparable public statement in support of Palestinian civilian populations, has not issued any public call for ceasefire or humanitarian access in Gaza, and has not published any communication specifically addressing ICJ proceedings or evolving humanitarian conditions as of the research cutoff. This asymmetry — one-sided solidarity expression from a company with deep structural ties to Israel — is what moves the V-POL Impact score above pure neutrality (which would score at approximately 1.0–2.0) into the 3.5 range. It is not, however, evidence of active political advocacy, lobbying, or financing of political organisations.
On the lobbying dimension, Teva Pharmaceuticals USA is a registered federal lobbyist under the Lobbying Disclosure Act, with documented annual expenditures in the range of several million dollars per cycle.2930 The disclosed issue areas are exclusively U.S. healthcare policy: generic drug pricing, the Inflation Reduction Act’s drug negotiation provisions, FDA regulatory pathways, patent dispute legislation, and opioid liability matters. No LDA filing identifying Israel-related policy areas — including U.S. foreign aid to Israel, arms transfer authorisation, anti-BDS federal legislation, or Middle East policy — was identified.2930 This finding is moderate-confidence pending a complete line-item review of all Teva LDA filings via the Senate LDA database.
Teva is absent from the UN OHCHR database of business enterprises with operations in Israeli settlements in the Occupied Palestinian Territory.31 Its principal Israeli manufacturing sites are within Israel’s pre-1967 lines. No evidence of Teva holding contracts with Israeli settlement local councils or industrial zones east of the Green Line was identified. No formal Brand Israel government public-diplomacy programme participation, no memoranda of understanding with Israeli ministries of strategic affairs or foreign affairs, and no co-branding with Israeli state tourism or “Start-Up Nation” campaigns were identified.32
Executive-level affiliations with organisations engaged in Israel-Palestine political advocacy — AIPAC, the Friends of the Israel Defense Forces (FIDF), the Jewish National Fund (JNF-KKL) — were not confirmed in available sources. This is a moderate-confidence finding: IRS Form 990 filings for FIDF, JNF, and affiliated foundations are public records but are not comprehensively indexed in training data at the individual named-donor level; live retrieval from ProPublica’s Nonprofit Explorer would be required to close this gap.33 In the anti-BDS certification context, Teva USA as a pharmaceutical supplier to state Medicaid programmes would likely be required to execute anti-BDS certifications in states with such procurement statutes, but no specific certification filing has been identified in available sources.34
The rubric mapping: Impact (I = 3.5) is Low-Mid — a single asymmetric solidarity statement goes modestly beyond pure neutrality but falls well short of active advocacy or political financing. Magnitude (M = 2.5) is Very Low–Low — one documented statement, no sustained campaign, no confirmed political donations to Israel-related causes. Proximity (P = 7.8) is at the upper end of the Moderate-Direct range — the corporate statement was issued under Teva’s own name and attributed to identified leadership (CEO Richard Francis), with no intermediary; the direct corporate actor is clearly identifiable.
The most significant evidence gap in V-POL concerns executive-level philanthropy. In large Israeli companies with prominent leadership, personal donations to FIDF, JNF, or similar organisations are common and are disclosed only in IRS Form 990 filings, which are indexed inconsistently in training data. If current or recent Teva executives are confirmed as major donors or board members of FIDF or AIPAC, the I-POL score could increase toward 8.0 (Severe — Direct Financing), which in the OR-dominant formula would add approximately 0.2 × (additional V-POL increment) to the composite — moving BRS from 520 to approximately 525–535, still firmly within Tier C.
A second counter-argument concerns the anti-BDS certification obligation. Several U.S. states require government contractors to certify non-boycott of Israel as a condition of Medicaid pharmaceutical procurement. Teva USA, as a large Medicaid supplier, would face this obligation in Texas, Florida, and other states. That Teva has almost certainly signed such certifications is a reasonable inference, but it cannot be confirmed from available sources and is appropriately excluded from scoring. If confirmed, the certification would constitute a formal legal commitment supporting Israeli commercial interests under state coercion — a materially different political act than a voluntary statement.
A third gap concerns updated corporate communications. No evidence of Teva issuing communications in 2024–2025 specifically addressing the ongoing conflict, ICJ proceedings, or humanitarian conditions in Gaza was identified within the available research base. This constitutes a material evidence gap requiring live-source verification. A sustained pattern of pro-Israel statements over the 2024–2025 period would increase both I-POL and M-POL toward the moderate-high range.
The absence of No BDS National Committee targeting is a relevant constraint on the political scoring. The BDS NC has explicitly stated it does not target Teva, citing Palestinian patient dependence on affordable Teva generic medicines.35 This is a significant civil society signal: the primary organising body for BDS campaigns has made a principled decision not to campaign against Teva, which is distinct from and more significant than mere failure to target.
| Entity | Type | Role / Relevance |
|---|---|---|
| Richard Francis | CEO | Issued solidarity statement; earnings call commentary on conflict |
| Dr. Rosemary Crane | Board Chair | Governance principal; no political affiliations identified |
| Kåre Schultz | Former CEO | Led restructuring; no documented Israel-related political activity |
| BDS National Committee | Civil society | Explicitly does not target Teva; cites patient access rationale |
| OHCHR Settlement Database | UN body | Teva absent; confirms no operations in occupied settlements |
| OpenSecrets.org | Lobbying monitor | Documents Teva USA LDA filings; no Israel-related lobbying identified |
| U.S. Senate LDA Database | Regulatory registry | Primary source for LDA filings; full review would require live access |
| PhRMA | Industry association | Teva member; lobbies on pharmaceutical pricing/regulatory policy only |
| Association for Accessible Medicines (AAM) | Industry association | Teva member; generic drug policy focus |
| FIDF / JNF-KKL / AIPAC | Israel-related advocacy orgs | No confirmed executive affiliations; gap requires IRS 990 live review |
| ProPublica Nonprofit Explorer | IRS 990 database | Required for closing executive philanthropy evidence gap |
| NCSL Anti-BDS Tracker | State legislature monitor | Tracks anti-BDS state statutes; Teva compliance probable but unconfirmed |
| Israeli Ministry of Foreign Affairs (Brand Israel) | Israeli state body | No Teva participation confirmed |
| Israeli Ministry of Strategic Affairs | Israeli state body | No Teva partnership confirmed |
Across all four domains, the most significant structural limitation is the gap between what is publicly documented in SEC filings, ESG reports, and NGO databases, and what may exist in undisclosed contractual, procurement, or philanthropic relationships. Teva is a large multinational with complex procurement and a substantial Israeli executive community; several categories of Israel-related activity — CBRN pharmaceutical supply (V-MIL), Israeli-origin enterprise software licensing (V-DIG), and executive-level donations to FIDF/JNF/AIPAC (V-POL) — are plausible but unconfirmed.
The OR-dominant BDS-1000 formula is specifically designed to ensure that these gaps, even if all resolved negatively, would not materially change the composite score. The structural anchor is V-ECON at 8.0, and the formula applies secondary domains at 20% of their combined weight. Teva’s economic integration with Israel is documented by primary sources — corporate law, Supreme Court rulings, stock exchange data, and SEC filings — that are immune to the open-source limitations affecting the other domains.
The BDS National Committee’s explicit non-targeting decision is a cross-domain signal worth noting at the composite level.35 The BDS NC’s reasoning — that Palestinian patients and communities depend on affordable Teva generic medicines — represents a substantive humanitarian counter-consideration that does not appear in the BDS-1000 rubric but is relevant context for recommended actions. Institutional investors and procurement bodies considering Teva engagement should weigh this alongside the complicity score.
The temporal limitation of the audit (research cutoff April–May 2026) means that any corporate communications, procurement decisions, or political activities by Teva in the context of the ongoing conflict after the research cutoff date are not captured. The V-POL evidence gap on 2024–2025 communications is the most likely domain where live-source updates would change the characterisation, though not necessarily the score band.
| Entity | Domain(s) | Type | Key Role |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. | All | Subject | Israeli-domiciled global generics leader; BRS 520, Tier C |
| Richard Francis | V-MIL, V-POL | CEO (current) | Solidarity statement; earnings call commentary |
| Kåre Schultz | V-ECON | Former CEO | Led 2017–2022 restructuring |
| Dr. Rosemary Crane | V-POL | Board Chair | Governance principal |
| IDF Medical Corps | V-MIL | Israeli military body | Recipient of wartime medicine donation |
| Magen David Adom | V-MIL | Israeli emergency service | Co-recipient of Oct 2023 donation |
| Israel Prison Service (IPS) | V-MIL | Israeli security body | Probable generics customer via market dominance |
| SIBAT | V-MIL | Israeli MoD export registry | Teva absent |
| Amazon Web Services (AWS) | V-DIG | U.S. cloud vendor | Teva preferred cloud provider since 2019; Teva is end-user |
| SAP | V-DIG | German ERP vendor | Teva global ERP backbone |
| IBM Watson Health / Merative | V-DIG | U.S. analytics (historical) | 2015–2022 collaboration; discontinued |
| Project Nimbus | V-DIG | Israeli govt cloud contract | Teva not a vendor; indirect exposure unconfirmed |
| Kiryat Atidim (Tel Aviv) | V-DIG, V-ECON | Technology park | Teva global HQ since 2022 |
| Tel Aviv Stock Exchange / TA-35 Index | V-ECON | Israeli financial institution | Teva is anchor constituent |
| Israeli Supreme Court | V-ECON | Israeli judiciary | 2022 ruling confirmed profit repatriation |
| Israel Tax Authority | V-ECON | Israeli state body | Transfer-pricing dispute; Preferred Enterprise incentives |
| Israel Innovation Authority | V-DIG, V-ECON | Israeli state body | R&D incentive programmes |
| Kfar Saba facility | V-ECON | Manufacturing site | Active oral solid dosage manufacturing |
| Netanya facility | V-ECON | R&D / manufacturing site | Active; global innovation centre |
| Ramat Hovav / Negev | V-MIL, V-ECON | API manufacturing | Active; chemical synthesis |
| Weizmann Institute / Yeda R&D | V-DIG, V-ECON | Academic/IP origin | Copaxone licensing; pre-2020 royalty relationship |
| Who Profits Research Center | V-MIL, V-DIG, V-POL | NGO | Company profile; no military/security classification |
| AFSC Investigate | V-MIL, V-DIG | NGO | Company profile; no military supply-chain finding |
| BDS National Committee | V-MIL, V-DIG, V-POL | Civil society | Explicitly does not target Teva |
| Norges Bank NBIM | V-MIL | Institutional investor | Has not excluded Teva |
| OHCHR Settlement Database | V-POL | UN body | Teva absent |
| OpenSecrets.org / LDA Database | V-POL | Lobbying monitors | Teva USA lobbying documented; no Israel-related issues |
| PhRMA / AAM | V-POL | Industry associations | Pharmaceutical policy lobbying only |
| FIDF / JNF-KKL / AIPAC | V-POL | Israel advocacy orgs | No confirmed executive affiliations |
| ProPublica Nonprofit Explorer | V-POL | IRS 990 database | Gap: executive philanthropy requires live retrieval |
| Domain | I | M | P | V-Score |
|---|---|---|---|---|
| V-MIL | 1.8 | 2.5 | 3.2 | 0.207 |
| V-DIG | 2.0 | 1.5 | 1.5 | 0.065 |
| V-ECON | 8.0 | 8.5 | 9.8 | 9.486 |
| V-POL | 3.5 | 2.5 | 7.8 | 0.979 |
| BRS | 520 | |||
| Tier | C |
The composite BRS of 520 is computed using the OR-dominant formula: V_MAX (V_ECON = 8.000) plus 20% of the sum of the three secondary domain scores (0.294 + 0.092 + 1.250 = 1.636), divided by 16, multiplied by 1,000. V-MIL and V-DIG contribute negligible weight because magnitude and proximity are well below the formula’s normalising denominator of 7. V-ECON dominates because both M (8.5/7 → capped at 1.0) and P (9.8/7 → capped at 1.0) are above the cap, yielding V_ECON = I × 1.0 × 1.0 = 8.0. V-POL contributes modestly (1.250) because I and M are low, even though P is high; the formula’s multiplicative structure prevents a high P from inflating the domain score when I and M are modest.
High-confidence findings:
– Teva’s Israeli domicile, 120-year incorporation history, Tel Aviv global headquarters, TA-35 membership, Preferred Enterprise tax incentives, and profit repatriation confirmed by Supreme Court ruling are established by primary legal and financial sources.
– Teva’s role as a technology buyer (AWS consumer) rather than technology provider is unambiguous across all reviewed source classes; the V-DIG Customer Cap and Directionality Rule are firmly applicable.
– Teva is absent from the OHCHR settlement database, SIBAT defence-export registry, and Norges Bank ethical-exclusion list.
Medium-confidence findings:
– The NIS 16 million wartime medicine donation to IDF field units and Israeli hospitals is documented; the existence of any standing IDF Medical Corps framework agreement beyond this donation is an unresolved gap.
– The V-MIL inference that Teva’s ~50% Israeli generics market share creates routine supply to IDF healthcare channels is well-grounded but not confirmed by a named contract.
– The absence of Israel-related lobbying in Teva’s LDA filings is documented but pending complete line-item review.
Open questions requiring live-source resolution:
1. Does Teva hold a standing supply agreement with the IDF Medical Corps distinct from the October 2023 donation?
2. Does Teva manufacture atropine auto-injectors or other CBRN medical countermeasures for the IDF or Home Front Command?
3. Have current or recent Teva executives made material donations to, or held board seats at, FIDF, JNF-KKL, or AIPAC? (Requires IRS Form 990 review via ProPublica.)
4. Have Teva USA state-level Medicaid contracts required execution of anti-BDS certifications under applicable state statutes?
5. Has Teva issued corporate communications on the conflict, ICJ proceedings, or Gaza humanitarian conditions during 2024–2025 beyond those captured at the research cutoff?
6. Does Teva license security or analytics software from Israeli-origin vendors (Check Point, CyberArk, NICE, Verint) not disclosed in public filings?
Tier stability: The Tier C classification (400–599) is robust. V-ECON at 8.0 anchors the BRS at 520. Resolving all open questions negatively (worst case across all four domains) would yield an estimated BRS of approximately 540–555, still within Tier C. Resolving all open questions positively (best case) would not move the score below 400, as V-ECON is definitively established and not subject to meaningful uncertainty.
For institutional investors and fund managers (Tier C — Engaged Monitoring):
The V-ECON score reflects foundational Israeli identity rather than a specific procurement or supply relationship that could be severed. Divestment pressure targeting Teva on BDS grounds conflicts directly with the BDS National Committee’s own stated position that Teva should not be targeted, given Palestinian patient dependence on affordable generic medicines.35 Shareholders seeking to engage on conflict-related concerns should prioritise: (a) requesting disclosure of any standing IDF/Ministry of Defence pharmaceutical supply contracts; (b) requesting a human rights due diligence policy mapping to the UN Guiding Principles with respect to occupied territories; and (c) seeking clarity on whether anti-BDS certifications have been executed under state procurement statutes and whether Teva regards these as consistent with its human rights commitments.
For procurement bodies and public-sector purchasers:
Teva’s Tier C classification reflects economic integration rather than direct supply of goods or services to Israeli military operations. No evidence identifies Teva as a weapons supplier, surveillance technology provider, or settlement-economy participant. Procurement screening frameworks focused on direct military supply or settlement products would not, on current evidence, reach Teva’s pharmaceutical products. Procurement bodies that screen on economic integration grounds should note that Teva generics are widely used in public health systems and that exclusion would require identification of therapeutically equivalent non-Israeli-origin alternatives — a non-trivial substitution exercise for some product classes.
For BDS campaign organisations:
The BDS National Committee’s standing non-targeting decision on Teva is the appropriate civil society reference point. Grassroots campaigns targeting Teva’s pharmaceutical products risk imposing concrete healthcare costs on Palestinian and other low-income populations without a proportionate political effect on Israeli state policy. Any campaign escalation should demonstrate that the BDS NC’s patient-access reasoning has been squarely addressed.
For academic and research institutions with Teva research collaborations:
No evidence of Teva research partnerships directly supporting military technology, surveillance, or settlement-economy activities was identified. Existing pharmaceutical research collaborations — including those with Israeli academic institutions such as the Weizmann Institute — fall within standard academic pharmaceutical research norms. Institutions with conflict-of-interest policies sensitive to Israeli state connections should note the indirect exposure via Teva’s foundational Israeli identity (V-ECON), while acknowledging the absence of direct V-MIL or V-DIG findings.
For journalists and civil society researchers:
The three open questions most likely to produce material new findings are: (1) IRS Form 990 review of FIDF, JNF-KKL, and AIPAC for Teva executive affiliations; (2) FOI or procurement database requests to Israeli MoD / Health Ministry for pharmaceutical framework contracts naming Teva; and (3) Israeli settlement industrial zone supply chain research to determine whether any Teva distribution node operates east of the Green Line. These are targeted, feasible investigative steps that would either close the evidence gaps or, if positive findings emerged, would justify a score review.
